All

Latest

FDA Approves First RSV Vaccine

In clinical trials, the vaccine significantly reduced the risk of developing RSV-associated lower respiratory tract disease by 82.6% and reduced the risk of developing severe RSV-associated lower respiratory tract disease by 94.1% in adults age 60 and older.

Products & Treatment

Latest

FDA Blocks 6,500 Flavored E-cigarette Products from 10 Companies

The companies' premarket tobacco product applications, which were for a variety of flavored e-cigarette products, did not provide sufficient evidence to show that permitting the marketing of these products would be appropriate for the protection of the public health, according to the FDA.